Delcath Systems, Inc. — FY2023 Form 10-K Summary
Business Context and Reporting Period
Delcath is an interventional oncology company focused on cancers originating in or metastatic to the liver. The filing covers the fiscal year ended December 31, 2023, with comparative results for 2022. HEPZATO KIT, a melphalan drug/device combination, received FDA approval on August 14, 2023 for specified adult patients with unresectable hepatic-dominant metastatic uveal melanoma. The first commercial U.S. treatment occurred in January 2024. CHEMOSAT is the device-only configuration marketed in Europe with separately sourced melphalan.
Financial Performance, Liquidity and Capital Structure
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Total revenue | $2.1 million | $2.7 million | Down $0.7 million |
| Gross profit | $1.4 million | $2.0 million | Down $0.6 million |
| Gross margin | Approximately 69% | Approximately 75% | Down approximately 6 percentage points |
| Research and development expense | $17.5 million | $18.6 million | Down 6% |
| Selling, general and administrative expense | $22.1 million | $17.3 million | Up 28% |
| Operating loss | $38.2 million | $33.9 million | Higher loss |
| Net loss | $47.7 million | $36.5 million | Higher loss |
| Basic and diluted loss per share | $2.94 | $4.12 | Improved due primarily to share count growth |
| Cash used in operating activities | $31.3 million | $25.0 million | Higher use |
Revenue consisted of $2.1 million of product revenue in 2023, compared with $2.5 million of product revenue and $0.2 million of other revenue in 2022. The company attributes the product-revenue decline primarily to the transition to direct CHEMOSAT selling beginning in March 2022 and the reduction in other revenue to the completion of license-related amortization.
At December 31, 2023, cash and cash equivalents were $12.6 million, restricted cash was $0.1 million, and short-term investments were $19.8 million. Total cash, cash equivalents and restricted cash increased to $12.7 million from $11.8 million at year-end 2022, but operating cash burn increased. Inventories rose to $3.3 million from $2.0 million, reflecting preparation for commercialization.
Total debt and convertible notes payable were $10.2 million net of discounts at December 31, 2023, including $5.2 million of current loan obligations and $4.9 million of current convertible notes. The Avenue term loan bears interest at 16.20% at year-end, is secured by substantially all company assets and intellectual property, and matures August 1, 2024. The filing identifies approximately $10.6 million of loan and convertible-note principal payments due in 2024, subject to potential conversion of up to $5.0 million of notes.
Material Changes Versus the Prior Comparable Period
- HEPZATO received FDA approval in August 2023, shifting the company from development toward U.S. commercialization.
- SG&A increased $4.8 million as the company expanded personnel and commercialization capabilities.
- R&D expense declined $1.1 million following lower NDA-related and regulatory-preparation costs.
- Net loss increased $11.2 million. The 2023 loss included an $8.0 million change in the fair value of warrant liabilities.
- The company raised approximately $23.0 million net through the March 2023 private placement and received approximately $35.0 million from warrant exercises.
- Common shares outstanding increased to 22.8 million at December 31, 2023 from 10.0 million, reflecting preferred-stock conversions and other equity issuances.
- Management reported that a previously identified material weakness related to share-based compensation expense was remediated by December 31, 2023.
Guidance, Outlook, Commentary and Risks
Management expects to continue incurring losses in 2024 and plans to expand HEPZATO commercialization, support CHEMOSAT in Europe and evaluate or initiate studies in additional liver-cancer indications, including colorectal, neuroendocrine, breast and intrahepatic cholangiocarcinoma. The filing does not provide quantitative revenue or profitability guidance.
CMS announced a permanent product-specific J-Code for HEPZATO, J9248, effective April 1, 2024. Management expects reimbursement access to support U.S. adoption, but coverage, payment levels, prior authorization and hospital economics remain uncertain. CHEMOSAT reimbursement in Europe varies by country; the filing states that it is approved for reimbursement in Germany.
The independent auditor included a going-concern explanatory paragraph. Management states that a substantial delay in activating HEPZATO treatment sites would require additional financing and could leave the company without sufficient funds to meet obligations within twelve months. The company expects significant additional capital may be required to sustain operations and commercialization.
- HEPZATO has limited commercial history and is approved only for its current uveal-melanoma indication.
- Product adoption depends on cancer-center activation, physician training under the REMS program, reimbursement and market acceptance.
- The company relies on third parties for melphalan and other critical components. It disclosed that its current melphalan manufacturer received FDA Form 483 observations in 2023 in an inspection unrelated to HEPZATO.
- The Avenue loan is secured by global assets and intellectual property; covenant breaches or missed payments could accelerate repayment and impair financing access.
- Supply, manufacturing, regulatory, product-liability, reimbursement, competition, cybersecurity and intellectual-property risks could materially affect commercialization.
- The company is subject to a medac settlement estimated at $1.0 million, recorded partly as current and partly as non-current liabilities, and disclosed a $0.9 million settlement payment to Lachman in 2023.
After year-end, the company closed a March 2024 private placement of common stock and pre-funded warrants for approximately $7.0 million of gross proceeds. It also entered into a five-year lease for approximately 18,000 square feet of Queensbury manufacturing and office space.
Most Important Facts for Investors to Verify
- Whether HEPZATO site activations and treatment volumes generate sufficient revenue to offset the company’s approximately $31 million annual operating cash burn.
- Actual reimbursement coverage, payment rates and patient access under J-Code J9248 and private-payor policies.
- Availability and regulatory status of melphalan and other critical components, including remediation of the supplier’s FDA observations.
- Sources and timing of financing for the approximately $10.6 million of 2024 debt and convertible-note principal obligations and ongoing operating needs.
- Terms, dilution and potential exercise or conversion of outstanding preferred stock, warrants, options and pre-funded warrants.
- Progress, cost and results of planned additional-indication studies and the CHOPIN Phase 2 trial.
- The company’s ability to resolve the auditor’s going-concern uncertainty through revenue growth, financing or other liquidity measures.